Dennis A. Eichenauer

TL;DR: This study evaluates coronavirus disease 19 (COVID‐19) associated invasive aspergillosis at a single centre in Cologne, Germany to evaluate patients with acute respiratory distress syndrome due to viral infection.

TL;DR: The aim of this work is to provide a systematic review and meta-analysis of the literature on canine coronavirus infection and its role in mortality and morbidity and to help clarify the role of immune checkpoints in this disease.

TL;DR: This open-label, randomised, parallel-group phase 3 trial investigated whether metabolic response determined by PET after two cycles of standard regimen eBEACOPP (PET-2) would allow adaption of treatment intensity, increasing it for PET-2-positive patients and reducing it forPET- 2-negative patients and showed non-inferiority in the 5-year progression-free survival estimates.

TL;DR: A phase 2 study is currently planned to optimize the dosing schedule in order to further improve the therapeutic efficacy of AFM13 and represent a well-tolerated, safe, and active targeted immunotherapy of Hodgkin lymphoma.

TL;DR: In this article, the authors evaluated the safety and efficacy of sarilumab, an interleukin-6 receptor inhibitor, in patients with severe (requiring supplemental oxygen by nasal cannula or face mask) or critical(requiring greater supplemental oxygen, mechanical ventilation, or extracorporeal support) COVID-19.